Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (Nasdaq: CGEN) will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 AM ET. The event will be held virtually, and interested parties can access a live webcast through the Investor Relations section of Compugen's website. A replay will be available for 90 days post-event. Compugen is focused on developing cancer immunotherapies, with notable candidates including COM701 and COM902. The company is headquartered in Israel and also has a presence in San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) announced the dosing of the first patient in a proof-of-concept study evaluating a triple combination of COM701, COM902, and pembrolizumab for metastatic microsatellite stable colorectal cancer (MSS CRC). This follow-up to previous positive findings aims to assess the treatment's efficacy in patients with liver metastases who have undergone up to three lines of therapy. Initial findings are expected by the end of 2023. The study is based on earlier Phase 1 data showing anti-tumor activity with the dual combination of COM701 and nivolumab. Compugen continues to advance its immunotherapy pipeline with promising candidates.
Compugen Ltd. (CGEN) reported its financial results for Q4 and full-year 2022, highlighting significant progress in clinical studies, including upcoming triple combination studies targeting metastatic microsatellite stable colorectal cancer (MSS CRC) and platinum-resistant ovarian cancer (PROC). The company has approximately $83.7 million in cash, expected to fund operations through 2024. Revenues for Q4 were $7.5 million, increasing from $6 million in 2021. Total net loss for the year was $33.7 million. Notably, AstraZeneca's advancement of a related program triggered a $7.5 million milestone payment, validating Compugen's pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced that AstraZeneca's bi-specific antibody, rilvegostomig, derived from Compugen's COM902, is set to progress into a Phase 3 trial in 2023. This trial will evaluate rilvegostomig's effectiveness as a PD-1/TIGIT bi-specific therapeutic. AstraZeneca is also expanding its Phase 2 program across various cancer indications. Compugen has received $10 million upfront and $15.5 million in milestone payments from AstraZeneca and is eligible for up to $200 million in additional milestones along with tiered royalties on future sales.
Compugen Ltd. (NASDAQ: CGEN) has announced a scheduled release of its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Interested parties can join the call via telephone or access the live webcast on the company's website. Compugen, based in Israel, specializes in cancer immunotherapy and predictive computational discovery, with product candidates COM701 and COM902 targeting solid tumors, and a partnered program with AstraZeneca in Phase 2 development.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming presentation at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET. The event will be held virtually, and a live webcast will be accessible through the Investor Relations section of Compugen's website, with a replay available afterward.
Compugen is pioneering computational target discovery for cancer immunotherapies, with product candidates like COM701 and COM902. The company also has a partnered program, AZD2936, in Phase 2 development by AstraZeneca.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET. CEO Anat Cohen-Dayag and other management team members will discuss the company's advancements in the DNAM-1 axis. A live webcast of the event will be available on Compugen's Investor Relations webpage, with a replay accessible afterward. Compugen specializes in cancer immunotherapies and has developed several promising product candidates, including COM701 and COM902 for solid tumors, with ongoing collaborations such as the AZD2936 program with AstraZeneca.
Compugen Ltd. (CGEN) reported encouraging results for its COM701 therapy combined with nivolumab ± BMS-986207 in heavily pretreated patients with platinum-resistant ovarian cancer. The study showed a 20% overall response rate and a disease control rate of 45%. Notably, three patients on triplet therapy have maintained responses for over nine months. The therapy demonstrated effectiveness across various cancer types, particularly in high-grade serous adenocarcinoma. Compugen plans to pursue further studies to enhance data supporting these findings.
Compugen Ltd. (CGEN) announced promising results for its COM701 treatment, combined with nivolumab and BMS-986207, showing a 20% overall response rate and 40% disease control rate in patients with platinum-resistant ovarian cancer. The data will be detailed at the ESMO Immuno-Oncology Congress on December 8, 2022. Management plans to discuss preliminary findings during an investor call on December 7, 2022. This treatment is crucial for patients lacking effective options.
Compugen Ltd. (NASDAQ: CGEN), a cancer immunotherapy firm, announced that CEO Anat Cohen-Dayag, Ph.D., will join a virtual fireside chat during the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 10:20 am ET. Interested parties can access the live webcast on Compugen's Investor Relations site, with a replay available post-event. The company focuses on developing innovative cancer therapies, including its proprietary product candidates COM701 and COM902, among other early-stage immuno-oncology programs.